Moneycontrol PRO

HomeNewsCompanies 2

Companies 2

Jump to Category

Sun Pharma: India remains bright spot amid uncertainty over hair loss drug
The company’s India business grew by more than 10 percent for four consecutive quarters outperforming the India pharma market
Business in the Week Ahead: August 5-9, 2024
RBI will release the monetary policy. Two new IPOs will open for subscription
Tata Motors Q1 results: Net profit zooms 74% on-year to Rs 5,566 crore, beats estimates
Tata Motors Q1 FY25 Results: JLR's revenue grew by 5.4 percent during April-June to GBP 7.3 billion with EBIT margins of 8.9 percent, up 30 basis points.
This long-term portfolio stock is now available at an attractive valuation
Mas Financial has reported a decent set of earnings with healthy asset quality
Advertisement
Remove Ad
Advertisement
Remove Ad
Advertisement
Remove Ad
Advertisement
Remove Ad
M&M's Q1 net profit falls 5% YoY to Rs 2,613 crore, SUV revenue market share rises
The Mumbai-based company's consolidated net profit went up by 20 percent at Rs 3,283 crore, as compared to Rs 2,745 crore in the year ago period
Chart of the Day: Why Suzlon's orders look more resilient this time
The company’s order book increased to the highest levels in its history in the June 2024 quarter
IndusInd Bank Q1 FY25: weak quarter, valuation attractive
The stock has headroom to re-rate if the bank handles asset quality stress well
Dr Reddy's Labs targets double-digit India growth for FY25
With sales of Rs 1,330 crore in Q1 of FY25, Dr. Reddy's ranks 10th in the domestic market, according to IQVIA data.
Advertisement
Remove Ad
LVMH's luxury wares earn top billing at Olympics opening
Grammy-winner Lady Gaga delivered an energetic performance of Renee 'Zizi' Jeanmaire's "Mon truc en plumes" (My Feather Friend) decked out in a Dior Haute Couture black feather jacket over a black satin bustier.
Cipla forecasts US sales run-rate at $235-$240 mn, margin to be stable at current levels
Cipla is aiming for a Q4 FY25 launch for its important respiratory drug, Advair, while awaiting the US FDA's response on corrective measures at its Goa facility, crucial for launching the chemotherapy drug Abraxane.
Tech Mahindra Q1 FY25 – great start to a turnaround year
Revenue growth, expansion in margins, and a traction in deals hold out growth hopes
In its biggest acquisition, Mankind Pharma tries to replicate its past success in M&A
Mankind Pharma is acquiring BSV at an enterprise value of Rs 13,630 crore. The last major acquisition it did was for Rs 1,872 crore.
Advertisement
Remove Ad
Mankind Pharma to buy Bharat Serums from Advent for Rs 13,630 crore
Earlier on July 25, Moneycontrol had reported that Mankind Pharma had edged ahead of EQT-ADIA consortium and emerged as the front-runner for the deal
Federal Bank Q1 FY25 – change of guard amid all-round strength
A gradual improvement in the RoA should lead to a valuation rerating

Axis Bank Q1 FY25 – slower earnings trajectory ahead, warrants caution
We see a high possibility of RoA compression in the near term
How large IT companies stack up on growth rates after June quarter
TCS and LTIMindtree are projected to lead FY25 revenue growth rates. But Infosys is fast gaining momentum
Advertisement
Remove Ad
Kotak Mahindra Bank Q1 FY25 – under the shadow of the embargo
The presence across the gamut of financial services augurs well for the bank in the long term
Wipro Q1 FY25: Growth remains elusive
Revenue decline and tepid guidance rule out valuation rerating for now
Infosys Q1 FY25 – Does all-round strength make the stock worthy of fresh allocation?
Deal ramp-up, BFSI demand revival, and the possible upside from large transformational deals once macro stabilises, should benefit the company
LTI Mindtree Q1 FY25 – strong quarter, encouraging outlook
Strong execution coupled with encouraging guidance on demand revival
Advertisement
Remove Ad
How Tata Power’s improved balance sheet is fuelling its capex
The net debt to equity ratio declined from 3 times in FY17 to less than one in FY24
What can Union Budget 2024 deliver to excite markets further?
Budget 2024-25: Focus on capex, support to consumer sentiment, and addressing rural distress while maintaining fiscal balance are key areas to watch
Investors of TCS, HCL should tally their optimism with ISG index
ISG, which tracks commercial outsourcing contracts, lowered the growth forecast for managed services
TCS Q1 FY25 – Why the underperformance should reverse now
Return of demand with improving macro among several positive factors
Advertisement
Remove Ad
KIMS should see results from Vizag hospital acquisition early
The hospital was incorporated in 2010 and generated a revenue of Rs 62 crore in FY23

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347